{
    "nctId": "NCT03175341",
    "briefTitle": "Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer",
    "officialTitle": "Phase I/II Randomized Study to Evaluate the Role of Intravenous Ascorbic Acid Supplementation to Conventional Neoadjuvant Chemotherapy in Women With Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Number of Patients With Adverse Events as a Measure of Safety and Tolerability",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status score \u22642;\n* Diagnosed high-risk breast cancers (tumours \u2265 2cm and/or locally advanced breast tumors) and scheduled to receive neoadjuvant chemotherapy;\n* Agree to avoid any additional supplemental ascorbic acid throughout the study;\n* Normal glucose-6- phosphate dehydrogenase (G6PD) activity;\n* Normal renal function (serum creatinine \u2264 1.2 mg/dl) and normal liver function;\n* No evidence of urolithiasis;\n* No evidence of chronic hemodialysis, iron overload (serum ferritin 500 ng/ml);\n* Not pregnant or lactating women\n\nExclusion Criteria:\n\n* Important psychosomatic diseases or known gastrointestinal disorders (ulcer, gastritis, colitis, ileitis);\n* Current smoking and/or alcohol consumption \u2265 3UI per day;\n* Current use of the following drugs:\n\nAspirin (exceeding 325 mg/day) Acetaminophen (exceeding 2 g/day) Glutathione Vitamin D (important doses)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}